Akihide Masumoto
Overview
Explore the profile of Akihide Masumoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sonehara K, Uwamino Y, Saiki R, Takeshita M, Namba S, Uno S, et al.
Cell Genom
. 2025 Mar;
5(3):100783.
PMID: 40043710
Vaccine immunogenicity is influenced by the vaccinee's genetic background. Here, we perform a genome-wide association study of vaccine-induced SARS-CoV-2-specific immunoglobulin G (IgG) antibody titers and T cell immune responses in...
2.
Kuwano A, Nagasawa S, Koga Y, Tanaka K, Yada M, Masumoto A, et al.
Exp Ther Med
. 2024 Jul;
28(3):337.
PMID: 39006455
The global coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected millions of lives, leading to significant morbidity and mortality. With >772 million...
3.
Kuwano A, Yada M, Tanaka K, Koga Y, Nagasawa S, Masumoto A, et al.
In Vivo
. 2024 Jun;
38(4):1854-1858.
PMID: 38936922
Background/aim: The landscape of treatments for hepatocellular carcinoma (HCC), including immune checkpoint inhibitors, has expanded significantly. However, unresectable HCC patients with portal vein tumor thrombus (PVTT) continue to face a...
4.
Kuwano A, Yada M, Koga Y, Tanaka K, Ohishi Y, Masumoto A, et al.
Oncol Lett
. 2024 May;
28(1):309.
PMID: 38784605
Lenvatinib is an approved therapy for advanced hepatocellular carcinoma (HCC). Recently, immune checkpoint inhibitors have been approved as frontline chemotherapies for HCC, and the tumor immune microenvironment (TIME) has been...
5.
Kuwano A, Yada M, Tanaka K, Koga Y, Nagasawa S, Masumoto A, et al.
Cancer Diagn Progn
. 2024 Mar;
4(2):111-116.
PMID: 38434920
Background/aim: Numerous agents, including immune checkpoint inhibitors, are now available for hepatocellular carcinoma (HCC) treatment. Most trials involving systemic chemotherapy have included patients with Child-Pugh class A, while excluding or...
6.
Kuwano A, Yada M, Tanaka K, Koga Y, Nagasawa S, Masumoto A, et al.
Cancer Diagn Progn
. 2024 Jan;
4(1):34-41.
PMID: 38173658
Background/aim: Atezolizumab in combination with bevacizumab is an approved systemic chemotherapy regimen for advanced hepatocellular carcinoma (HCC). However, immune checkpoint inhibitors (ICIs), such as atezolizumab, frequently lead to immune-related adverse...
7.
Nagasawa S, Kuwano A, Tanaka K, Yada M, Masumoto A, Motomura K
Cancer Diagn Progn
. 2023 Nov;
3(6):660-666.
PMID: 37927810
Background/aim: In radiofrequency ablation (RFA) treatment of hepatocellular carcinoma (HCC), the therapeutic effect depends on the appropriate position of the electrode. To improve the accuracy of the electrode needle position,...
8.
Motomura K, Kuwano A, Tanaka K, Koga Y, Masumoto A, Yada M
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686621
In the systemic drug treatment of hepatocellular carcinoma, only the tyrosine kinase inhibitor (TKI) sorafenib was available for a period. This was followed by the development of regorafenib as a...
9.
Kuwano A, Miyazaki M, Yada M, Tanaka K, Koga Y, Masumoto A, et al.
Exp Ther Med
. 2023 Aug;
26(3):441.
PMID: 37614433
Current antiviral therapies cannot achieve eradication of hepatitis B virus (HBV) and can reduce but not eliminate the risk of hepatocellular carcinoma (HCC) in patients with chronic HBV infection. The...
10.
Kuwano A, Yada M, Miyazaki Y, Tanaka K, Koga Y, Ohishi Y, et al.
Cancer Diagn Progn
. 2023 Jul;
3(4):468-474.
PMID: 37405218
Background/aim: Systemic chemotherapy with atezolizumab plus bevacizumab is approved for unresectable hepatocellular carcinoma (HCC). It is necessary to identify probable predictive biomarkers for chemotherapies. HCC with rim arterial-phase enhancement (APHE)...